Skip to main content
Erschienen in: Current Urology Reports 10/2014

01.10.2014 | Lower Urinary Tract Symptoms & Voiding Dysfunction (H Goldman and G Badlani, Section Editors)

The Evaluation and Management of Refractory Neurogenic Overactive Bladder

verfasst von: Raj Kurpad, Michael J. Kennelly

Erschienen in: Current Urology Reports | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Patients with neurologic disease commonly develop overactive bladder (OAB) symptoms of urgency, frequency, and/or urge incontinence that remain bothersome despite oral pharmacologic therapy. Management of refractory OAB in the neurogenic population is a complex issue with no uniform treatment strategy. When treatment fails or patients generally are dissatisfied with the adverse effects of oral therapy, available options include sacral neuromodulation, percutaneous tibial nerve stimulation (PTNS), botulinum toxin injections, and lower urinary tract reconstruction such as augmentation cystoplasty. A thorough knowledge and understanding of available and emerging treatment options for neurogenic detrusor overactivity is paramount to assisting clinicians in choosing an appropriate treatment. This article reviews the non-pharmacologic treatment options for neurogenic OAB, mainly botulinum toxin, neuromodulation, and lower urinary tract reconstruction, and discusses important relevant studies.
Literatur
1.•
Zurück zum Zitat Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor over-activity. Urology. 2003;62(Suppl):28. An excellent review of the pathophysiology of micturition. Additionally, this article provides an informative overview of overactive bladder.PubMedCrossRef Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor over-activity. Urology. 2003;62(Suppl):28. An excellent review of the pathophysiology of micturition. Additionally, this article provides an informative overview of overactive bladder.PubMedCrossRef
2.
Zurück zum Zitat Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167.PubMedCrossRef Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167.PubMedCrossRef
3.
Zurück zum Zitat Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth International consultation on incontinence recommendations of the international scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29:213–40.PubMedCrossRef Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth International consultation on incontinence recommendations of the international scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29:213–40.PubMedCrossRef
4.
Zurück zum Zitat Cruz F, Siva C. Refractory neurogenic detrusor overactivity. Int J Clin Pract. 2006;60:22–5.CrossRef Cruz F, Siva C. Refractory neurogenic detrusor overactivity. Int J Clin Pract. 2006;60:22–5.CrossRef
5.•
Zurück zum Zitat Wein AJ. Lower urinary tract dysfunction in neurologic injury and disease. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh urology. 9th ed. New York: Saunders; 2007. p. 2011–45. The definitive standard and authority on defining, detailing, and presenting the evaluation and management of neurogenic bladder. Wein AJ. Lower urinary tract dysfunction in neurologic injury and disease. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh urology. 9th ed. New York: Saunders; 2007. p. 2011–45. The definitive standard and authority on defining, detailing, and presenting the evaluation and management of neurogenic bladder.
6.
Zurück zum Zitat Linsenmeyer TA, Linsenmeyer MA. Impact of annual urodynamic evaluations on guiding bladder management in individuals with spinal cord injuries. J Spinal Cord Med. 2013;36(5):420–6.PubMedCrossRefPubMedCentral Linsenmeyer TA, Linsenmeyer MA. Impact of annual urodynamic evaluations on guiding bladder management in individuals with spinal cord injuries. J Spinal Cord Med. 2013;36(5):420–6.PubMedCrossRefPubMedCentral
7.
Zurück zum Zitat Larijani FJ, Moghtaderi M, Hajizadeh N, Assadi F. Preventing kidney injury in children with neurogenic bladder dysfunction. Int J Prev Med. 2013;4(12):1359–64.PubMedPubMedCentral Larijani FJ, Moghtaderi M, Hajizadeh N, Assadi F. Preventing kidney injury in children with neurogenic bladder dysfunction. Int J Prev Med. 2013;4(12):1359–64.PubMedPubMedCentral
8.•
Zurück zum Zitat Kennelly MJ, Devoe WB. Overactive bladder: pharmacologic treatments in the neurogenic population. Rev Urol. 2008;10(3):182–91. An excellent overview of the medical therapies available for the treatment of neurogenic detrusor overactivity. The authors also offer a broad outline of additional further therapies.PubMedPubMedCentral Kennelly MJ, Devoe WB. Overactive bladder: pharmacologic treatments in the neurogenic population. Rev Urol. 2008;10(3):182–91. An excellent overview of the medical therapies available for the treatment of neurogenic detrusor overactivity. The authors also offer a broad outline of additional further therapies.PubMedPubMedCentral
9.
Zurück zum Zitat Sahai A, Cortes E, Seth J, Khan MS, Panicker J, Kelleher C, et al. Neurogenic detrusor overactivity in patients with spinal cord injury: evaluation and management. Curr Urol Rep. 2011;12(6):404–12.PubMedCrossRef Sahai A, Cortes E, Seth J, Khan MS, Panicker J, Kelleher C, et al. Neurogenic detrusor overactivity in patients with spinal cord injury: evaluation and management. Curr Urol Rep. 2011;12(6):404–12.PubMedCrossRef
10.
Zurück zum Zitat Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA. 2011;305(1):89–90.PubMedCrossRef Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA. 2011;305(1):89–90.PubMedCrossRef
11.•
Zurück zum Zitat Linsenmeyer TA. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. J Spinal Cord Med. 2013;36(5):402–19. A state-of-the-art review that provides excellent insight into the mechanism of action, as well as a review of the most current evidence available to support the use of botulinum toxin in the management of refractory neurogenic bladder.PubMedCrossRefPubMedCentral Linsenmeyer TA. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. J Spinal Cord Med. 2013;36(5):402–19. A state-of-the-art review that provides excellent insight into the mechanism of action, as well as a review of the most current evidence available to support the use of botulinum toxin in the management of refractory neurogenic bladder.PubMedCrossRefPubMedCentral
12.
Zurück zum Zitat Grosse J, Kramer G, Stöhrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol. 2005;47(5):653–9.PubMedCrossRef Grosse J, Kramer G, Stöhrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol. 2005;47(5):653–9.PubMedCrossRef
13.
Zurück zum Zitat Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692–7.PubMedCrossRef Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692–7.PubMedCrossRef
14.
Zurück zum Zitat Gamé X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudié I, DeBoissezon X, Malavaud B, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of urinary tract infections. Eur Urol. 2008;53(3):613–8.PubMedCrossRef Gamé X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudié I, DeBoissezon X, Malavaud B, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of urinary tract infections. Eur Urol. 2008;53(3):613–8.PubMedCrossRef
15.
Zurück zum Zitat Giannantoni A, Mearini E, Del Zingaro M, Porena M. Six-year follow-up of botulinum toxin A intradetrusotial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol. 2009;55(3):705–11.PubMedCrossRef Giannantoni A, Mearini E, Del Zingaro M, Porena M. Six-year follow-up of botulinum toxin A intradetrusotial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol. 2009;55(3):705–11.PubMedCrossRef
16.
Zurück zum Zitat Carlson JJ, Hansen RN, Dmochowski RR, Globe DR, Colayco DC, Sullivan SD. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States. Clin Ther. 2013;35(4):414–24.PubMedCrossRef Carlson JJ, Hansen RN, Dmochowski RR, Globe DR, Colayco DC, Sullivan SD. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States. Clin Ther. 2013;35(4):414–24.PubMedCrossRef
17.
Zurück zum Zitat Kennelly M, Dmochowski R, Ethans K, et al. Long-term efficacy and safety of onabotulinum toxin A in patients with urinary incontinence due to neurogenicdetrusor overactivity: an interim analysis. Urology. 2013;81(3):491–7.PubMedCrossRef Kennelly M, Dmochowski R, Ethans K, et al. Long-term efficacy and safety of onabotulinum toxin A in patients with urinary incontinence due to neurogenicdetrusor overactivity: an interim analysis. Urology. 2013;81(3):491–7.PubMedCrossRef
18.
Zurück zum Zitat Anderson RU, Orenberg EK, Glowe P. Onabotulinum toxin A office treatment for neurogenic bladder incontinence in Parkinson's disease. Urology. 2014;83(1):22–7.PubMedCrossRef Anderson RU, Orenberg EK, Glowe P. Onabotulinum toxin A office treatment for neurogenic bladder incontinence in Parkinson's disease. Urology. 2014;83(1):22–7.PubMedCrossRef
19.
Zurück zum Zitat Chancellor MB, Patel V, Leng WW, Shenot PJ, Lam W, Globe DR, et al. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. Neurology. 2013;81(9):841–8.PubMedCrossRefPubMedCentral Chancellor MB, Patel V, Leng WW, Shenot PJ, Lam W, Globe DR, et al. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. Neurology. 2013;81(9):841–8.PubMedCrossRefPubMedCentral
20.
Zurück zum Zitat Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32(3):242–9.PubMedCrossRef Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32(3):242–9.PubMedCrossRef
21.
Zurück zum Zitat Johnson M. Transcutaneous electrical nerve stimulation. In: Watson T, editor. Electrotherapy: evidence-based practice. Edinburgh: Churchill Livingstone; 2008. p. 253–96. Johnson M. Transcutaneous electrical nerve stimulation. In: Watson T, editor. Electrotherapy: evidence-based practice. Edinburgh: Churchill Livingstone; 2008. p. 253–96.
23.
24.
Zurück zum Zitat Amundsen CL, Romero AA, Jamison MG, Webster GD. Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure? Urology. 2005;66:746–50.PubMedCrossRef Amundsen CL, Romero AA, Jamison MG, Webster GD. Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure? Urology. 2005;66:746–50.PubMedCrossRef
26.•
Zurück zum Zitat Bartley J, Gilleran J, Peters K. Neuromodulation for overactive bladder. Nat Rev Urol. 2013;10(9):513–21. doi:10.1038/nrurol.2013.143. A detailed review of the mechanism of action and a review of the current literature regarding the various modalities of neuromodulation that may be used in the management of refractory neurogenic bladder.PubMed Bartley J, Gilleran J, Peters K. Neuromodulation for overactive bladder. Nat Rev Urol. 2013;10(9):513–21. doi:10.​1038/​nrurol.​2013.​143. A detailed review of the mechanism of action and a review of the current literature regarding the various modalities of neuromodulation that may be used in the management of refractory neurogenic bladder.PubMed
27.
Zurück zum Zitat Peters KM, Kandagatla P, Killinger KA, Wolfert C, Boura JA. Clinical outcomes of sacral neuromodulation in patients with neurologic conditions. Urology. 2013;81(4):738–43.PubMedCrossRef Peters KM, Kandagatla P, Killinger KA, Wolfert C, Boura JA. Clinical outcomes of sacral neuromodulation in patients with neurologic conditions. Urology. 2013;81(4):738–43.PubMedCrossRef
28.
Zurück zum Zitat Lombardi G, Musco S, Celso M, Del Corso F, Del Popolo G. Sacral neuromodulation for neurogenic non-obstructive urinary retention in incomplete spinal cord patients: a ten-year follow-up single-centre experience. Spinal Cord. 2014;52(3):241–5.PubMedCrossRef Lombardi G, Musco S, Celso M, Del Corso F, Del Popolo G. Sacral neuromodulation for neurogenic non-obstructive urinary retention in incomplete spinal cord patients: a ten-year follow-up single-centre experience. Spinal Cord. 2014;52(3):241–5.PubMedCrossRef
29.
Zurück zum Zitat Amarenco G et al. Urodynamic effect of acute transcutaneous posterior tibial nerve stimulation in overactive bladder. J Urol. 2003;169:2210–5.PubMedCrossRef Amarenco G et al. Urodynamic effect of acute transcutaneous posterior tibial nerve stimulation in overactive bladder. J Urol. 2003;169:2210–5.PubMedCrossRef
30.
Zurück zum Zitat Zecca C, Digesu GA, Robshaw P, Singh A, Elneil S, Gobbi C. Maintenance percutaneous posterior nerve stimulation for refractory lower urinary tract symptoms in patients with multiple sclerosis: an open label, multicenter, prospective study. J Urol. 2014;191(3):697–702.PubMedCrossRef Zecca C, Digesu GA, Robshaw P, Singh A, Elneil S, Gobbi C. Maintenance percutaneous posterior nerve stimulation for refractory lower urinary tract symptoms in patients with multiple sclerosis: an open label, multicenter, prospective study. J Urol. 2014;191(3):697–702.PubMedCrossRef
31.•
Zurück zum Zitat Sajadi KP, Goldman HB. Bladder augmentation and urinary diversion for neurogenic LUTS: current indications. Curr Urol Rep. 2012;13(5):389–93. An overview of the many types of urinary augmentation and diversion surgeries, their indications, and their techniques.PubMedCrossRef Sajadi KP, Goldman HB. Bladder augmentation and urinary diversion for neurogenic LUTS: current indications. Curr Urol Rep. 2012;13(5):389–93. An overview of the many types of urinary augmentation and diversion surgeries, their indications, and their techniques.PubMedCrossRef
32.
Zurück zum Zitat Biers SB, Venn SN, Greenwell TJ. The past, present and future of augmentation cystoplasty. BJUI. 2011;109:1280–93.CrossRef Biers SB, Venn SN, Greenwell TJ. The past, present and future of augmentation cystoplasty. BJUI. 2011;109:1280–93.CrossRef
33.
Zurück zum Zitat Gurung, Attar KH, Abdul-Rahman A, et al. Long-term outcomes of augmentation ileocystoplasty in patients with spinal cord injury: a minimum of 10 years of follow-up. BJU Int. 2012;109:1236–42.PubMedCrossRef Gurung, Attar KH, Abdul-Rahman A, et al. Long-term outcomes of augmentation ileocystoplasty in patients with spinal cord injury: a minimum of 10 years of follow-up. BJU Int. 2012;109:1236–42.PubMedCrossRef
34.
Zurück zum Zitat Vaida P, Pinter AB, Harangi F, et al. Metabolic findings after colocystoplasty in children. Urology. 2003;62:542–6.CrossRef Vaida P, Pinter AB, Harangi F, et al. Metabolic findings after colocystoplasty in children. Urology. 2003;62:542–6.CrossRef
35.
Zurück zum Zitat Kälble T, Hofmann I, Thüroff JW, et al. Secondary malignancies in urinary diversions. Urologe A. 2012;51(4):500. 502-6.PubMedCrossRef Kälble T, Hofmann I, Thüroff JW, et al. Secondary malignancies in urinary diversions. Urologe A. 2012;51(4):500. 502-6.PubMedCrossRef
36.
Zurück zum Zitat Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20(2):130–40.PubMed Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20(2):130–40.PubMed
Metadaten
Titel
The Evaluation and Management of Refractory Neurogenic Overactive Bladder
verfasst von
Raj Kurpad
Michael J. Kennelly
Publikationsdatum
01.10.2014
Verlag
Springer US
Erschienen in
Current Urology Reports / Ausgabe 10/2014
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-014-0444-z

Weitere Artikel der Ausgabe 10/2014

Current Urology Reports 10/2014 Zur Ausgabe

Pediatric Urology (M Castellan and R Gosalbez, Section Editors)

Vesicoureteral Reflux: Current Management in Children

Men's Health (R Carrion and C Yang, Section Editors)

Surgical Management of Peyronie’s Disease

Lower Urinary Tract Symptoms & Voiding Dysfunction (H Goldman and G Badlani, Section Editors)

Lower Urinary Tract Symptoms in Women with Diabetes Mellitus: A Current Review

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.